Arch Biopartners (ARCH) Stock Statistics & Valuation Metrics

Arch Biopartners has a market cap or net worth of C$62.50M. The enterprise value is C$36.94M.

Arch Biopartners has 67,933,290 shares outstanding. The number of shares has decreased by -2.65% in one year.

Arch Biopartners’s return on equity (ROE) is 0.40 and return on invested capital (ROIC) is 145.70%.

The current PE Ratio of Arch Biopartners is ―. Arch Biopartners’s PEG ratio is 0.88.

In the last 12 months, Arch Biopartners had revenue of 0.00 and earned -1.55M in profits. Earnings per share was -0.02.

In the last 12 months, operating cash flow was -1.09M and capital expenditures 0.00, giving a free cash flow of -1.09M billion.

Arch Biopartners pays an annual dividend of ―, resulting in a dividend yield of ―

Arch Biopartners upcoming earnings date is Aug 27, 2026, TBA (Confirmed).

Arch Biopartners as a current ratio of 0.03, with Debt / Equity ratio of -74.94%

In the past 12 months, Arch Biopartners has paid 0.00 in taxes.

Arch Biopartners EV to EBITDA ratio is -67.06, with an EV/FCF ratio of -54.80.

Arch Biopartners has C$436.76K in cash and marketable securities with C$2.73M in debt, giving a net cash position of -C$2.29M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Arch Biopartners is ―, which is 11.43% higher than the current price. The consensus rating is ―